The settlement, reached April 27, resolves allegations that from 2010 to 2015, Indivior promoted Suboxone to physicians who prescribed it without a legitimate medical purpose. It also settles allegations that Indivior made misleading claims about Suboxone’s risk of diversion, abuse and accidental pediatric exposure.
Additionally, the settlement resolves allegations that Indivior fraudulently informed the FDA that the drug had been discontinued to deter generic competitors from entering the market.
Last November, Indivior agreed to permanently disband its Suboxone sales force and take steps to prevent promoting it to healthcare providers at high risk of inappropriate prescribing.
In an April 28 news release, Indivior said the settlement announcement was “administrative in nature” and formalized agreements regarding Suboxone marketing it had made last November.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
